AbbVie enters world of pain in up to $715M deal with China’s Haisco

By /

The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavax.

Scroll to Top